Circassia Pharmaceuticals PLC (CIR) Price Target Lowered to GBX 140 at JPMorgan Chase & Co.
Circassia Pharmaceuticals PLC (LON:CIR) had its target price trimmed by JPMorgan Chase & Co. from GBX 170 ($2.22) to GBX 140 ($1.83) in a research report released on Wednesday. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.
CIR has been the topic of a number of other research reports. Royal Bank Of Canada downgraded Circassia Pharmaceuticals PLC to a sector performer rating and reduced their target price for the stock from GBX 430 ($5.61) to GBX 105 ($1.37) in a report on Tuesday, June 21st. Barclays PLC initiated coverage on Circassia Pharmaceuticals PLC in a report on Tuesday, June 21st. They set an overweight rating and a GBX 170 ($2.22) target price on the stock. Peel Hunt reaffirmed an under review rating on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Numis Securities Ltd reaffirmed an under review rating on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Finally, Stifel Nicolaus downgraded Circassia Pharmaceuticals PLC to a hold rating in a report on Tuesday, June 21st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of GBX 183.33 ($2.39).
Shares of Circassia Pharmaceuticals PLC (LON:CIR) traded up 1.07% on Wednesday, reaching GBX 94.50. The company had a trading volume of 129,508 shares. The stock has a 50 day moving average price of GBX 94.79 and a 200-day moving average price of GBX 179.06. Circassia Pharmaceuticals PLC has a 12 month low of GBX 81.05 and a 12 month high of GBX 322.90. The company’s market capitalization is GBX 269.12 million.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.